59052-85-6

Basic information

• Product Name: 2-PIPERAZIN-1-YLMETHYL-1H-BENZOIMIDAZOLE
• Synonyms: TIMTEC-BB SBB010117;2-PIPERAZIN-1-YLMETHYL-1H-BENZOIMIDAZOLE;1-[(1H-Benzimidazol-2-yl)methyl]piperazine;2-[(Piperazin-1-yl)methyl]-1H-benzimidazole
• CAS NO: 59052-85-6
• Molecular Formula: C12H16N4
• Molecular Weight: 216.28
• Mol File: 59052-85-6.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-PIPERAZIN-1-YLMETHYL-1H-BENZOIMIDAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-PIPERAZIN-1-YLMETHYL-1H-BENZOIMIDAZOLE(59052-85-6)
• EPA Substance Registry System: 2-PIPERAZIN-1-YLMETHYL-1H-BENZOIMIDAZOLE(59052-85-6)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 59052-85-6(Hazardous Substances Data)

Usage

General Description

2-PIPERAZIN-1-YLMETHYL-1H-BENZOIMIDAZOLE is a chemical compound with potential pharmacological properties. It contains a piperazine ring and a benzimidazole ring, which are commonly found in various pharmaceutical drugs. 2-PIPERAZIN-1-YLMETHYL-1H-BENZOIMIDAZOLE may have potential applications as a medication for treating various conditions, due to its structural features and potential interactions with biological systems. Further research and development is needed to fully understand the potential uses and effects of this compound.

Upstream product

• 4857-04-9 2-chloromethyl-1H-benzimidazole 
• 110-85-0 piperazine 
• 95-54-5 1,2-diamino-benzene 

Downstream Products

• 1354972-24-9 1-(4-((1H-benzo[d]imidazol-2-yl)methyl)piperazin-1-yl)-2-(2,4-difluoro phenyl)-3-(1H-1,2,4-triazol-1-yl)propan-2-ol 

Relevant articles and documents

Design, synthesis, characterization and evaluation of 1,3,5-triazine-benzimidazole hybrids as multifunctional acetylcholinesterases inhibitors

A series of hybrids of benzimidazole and 1,3,5-triazine were designed and synthesized and evaluated as multi-target agents for the treatment of Alzheimer's disease. 24 compounds were designed, synthesized and identified by NMR, IR, HRMS and single-crystal X-ray diffraction studies. The compound 6c had the crystal system of orthorhombic and the space group of P212121. The cholinesterase inhibitory activity of synthesized compounds was measured using colorimetric Ellman's method. Most 1,3,5-triazine-benzimidazole hybrids showed potent acetylcholinesterase-inhibition activities and weak butyrylcholinesterase inhibitory activities. Compound 9f possessed the best acetylcholinesterase inhibitory activity with the IC50 of 0.044 μM, which is better than donepezil (0.052 μM). Molecular docking and molecular dynamics simulations demonstrated that there is a stable interaction between compound 9f and acetylcholinesterase. Simultaneously, experiments have also proved that compound 9f has good metal chelating properties. ADMET in silico prediction results suggest the compound can pass through the blood-brain barrier well and have good drug similarity. So, compound 9f could be a multi-target agent for the treatment of Alzheimer's disease.

PYRAZOLOPYRIMIDIN-2-YL DERIVATIVES AS JAK INHIBITORS

New pyrazolopyridmiin-2-yl derivatives are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).